Published in
Springer Nature [academic journals on nature.com], Leukemia, 7(26), p. 1693-1695, 2012
DOI: 10.1038/leu.2012.8
Links
Tools
Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases
Journal article published in 2012 by
E. Lierman,
S. Smits,
J. Cools,
B. Dewaele 
,
M. Debiec-Rychter,
P. Vandenberghe
,
M. Debiec-Rychter,
P. Vandenberghe
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 